<!DOCTYPE html>
<html>
<meta charset="UTF-8">
<head>
    <title>CXCL3——CXCR2 - PMID Details</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            margin: 20px;
            line-height: 1.6;
            color: #333;
        }

        h1 {
            text-align: center;
            font-size: 2.5em;
            color: #2c3e50;
            margin-bottom: 20px;
        }

        /* Navbar Styles */
        nav {
            background-color: #2c3e50;
            padding: 10px 20px;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
            color: white;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        nav .navbar-left, nav .navbar-right {
            display: flex;
            align-items: center;
        }

        nav a {
            color: white;
            text-decoration: none;
            margin: 0 15px;
            font-size: 1.1em;
            transition: color 0.3s ease;
        }

        nav a:hover {
            color: #f39c12;
        }

        nav .divider {
            color: #ecf0f1;
            margin: 0 10px;
        }

        /* Page Footer */
        footer {
            margin-top: 40px;
            padding: 10px 20px;
            background-color: #f7f7f7;
            color: #333;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        /* Tab and Content Styles */
        .tab {
            display: flex;
            flex-wrap: wrap;
            justify-content: center;
            margin-bottom: 20px;
        }

        .tab button {
            padding: 10px 20px;
            margin: 5px;
            margin-bottom: 10px;
            cursor: pointer;
            background-color: #f4f4f4;
            border: 2px solid #ddd;
            border-radius: 5px;
            font-size: 1.1em;
            transition: background-color 0.3s ease;
            flex-basis: calc(10% - 10px);
            box-sizing: border-box;
        }

        .tab button:hover {
            background-color: #ecf0f1;
        }

        .tab button.active {
            background-color: #3498db;
            color: white;
            border-color: #2980b9;
        }

        .tabcontent {
            display: none;
            padding: 20px;
            margin-top: 10px;
            background-color: #ecf0f1;
            border-radius: 5px;
            box-shadow: 0px 0px 10px rgba(0, 0, 0, 0.1);
        }

        .tabcontent.active {
            display: block;
        }

        .tabcontent h2 {
            font-size: 2em;
            color: #2980b9;
        }

        .tabcontent p {
            font-size: 1.2em;
            line-height: 1.8;
        }

        /* Emphasize Title and Abstract */
        .title, .abstract {
            background-color: #f9f9f9;
            padding: 20px;
            margin: 10px 0;
            border-left: 5px solid #2980b9;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
        }

        .abstract {
            border-left: 5px solid #e74c3c;
        }
    </style>
    <script>
        function adjustTabStyle() {
            var tabCount = document.querySelectorAll('.tab button').length;
            var tabContainer = document.querySelector('.tab');

            if (tabCount > 10) {
                tabContainer.classList.add('small-tabs');
            }
        }

        function openTab(evt, tabId) {
            document.querySelectorAll(".tabcontent").forEach(tab => tab.style.display = "none");
            document.querySelectorAll(".tablinks").forEach(link => link.classList.remove("active"));
            document.getElementById(tabId).style.display = "block";
            evt.currentTarget.classList.add("active");
        }

        window.onload = adjustTabStyle;
    </script>
</head>
<body>
    <nav>
        <div class="navbar-left">
            <a href="">ConnectomeDB</a>
            <a href="https://comp.med.yokohama-cu.ac.jp/collab/connectomeDB/">Home</a>
            <a href="https://comp.med.yokohama-cu.ac.jp/collab/connectomeDB/database.html">Database</a>
        </div>
        <div class="navbar-right">
            <a href="https://www-user.yokohama-cu.ac.jp/~bioinfo/">YCU Bioinformatics Lab</a>
            <span class="divider">|</span>
            <a href="https://perkins.org.au/research/labs/cancer-program/systems-biology-and-genomics-overview/">Perkins Systems Biology & Genomics Lab</a>
        </div>
    </nav>

    <h1>PMID Details for CXCL3——CXCR2</h1>

    <div class="tab">
        <button class="tablinks active" onclick="openTab(event, 'tab8702798')">8702798</button><button class="tablinks " onclick="openTab(event, 'tab8702798')">8702798</button>
    </div>

    <div class="tabcontent" id="titleTab">
        <div class="title">
            <h2>Title</h2>
            <p>{{TITLE}}</p>
            <i> Journal:{{JOURNAL}}; Year Published:{{YEAR}}</i>   
        </div>
    </div>

    <div class="tabcontent" id="abstractTab">
        <div class="abstract">
            <h2>Abstract</h2>
            <p>{{ABSTRACT}}</p>
        </div>
    </div>

    
                <div id="tab8702798" class="tabcontent active">
                    <h2>The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor.</h2>
                    <h3>The Journal of biological chemistry; 1996</h3>
                    <p>Interleukin-8 (IL-8), growth-related oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2 (NAP-2), epithelial cell-derived neutrophil activating peptide- 78 (ENA-78), and granulocyte chemoattractant protein-2 are potent neutrophil chemoattractants 40-90% identical in amino acid sequence that comprise a subgroup of human CXC chemokines defined by the conserved sequence motif glutamic acid-leucine-arginine (ELR). Two human chemotactic receptor subtypes for IL-8, named IL-8 receptors (IL8R) A and B, have been cloned. They are 78% identical in amino acid sequence, coexpressed in neutrophils, and distinguished by their different selectivities for GROalpha and NAP-2. Their selectivity for other ELR+ CXC chemokines has not been previously reported. By measuring calcium flux in human embryonic kidney 293 cells transfected with plasmids encoding IL8RA or IL8RB, we have now defined receptor selectivity for GRObeta, GROgamma, and ENA-78. The rank order of agonist potency, based on inspection of the mean effective concentration values (EC50), for IL8RB was GROgamma (1 nM) > IL-8 (4 nM) approximately GROalpha (5 nM) approximately GRObeta (4 nM) approximately NAP-2 (7 nM) > ENA-78 (11 nM), and for IL8RA was IL-8 (4 nM) >>> ENA-78 (40 nM) approximately NAP-2 (45 nM) > GROalpha (63 nM) approximately GROgamma (65 nM) >> GRObeta. The maximal response of IL8RA to IL-8 was at least 2-fold greater than the other five chemokines. All six agonists for IL8RB competed for high affinity 125I-IL-8, -GROalpha, -NAP-2, and -ENA-78 binding sites at IL8RB. GROalpha, GRObeta, GROgamma, NAP-2, and ENA-78 competed weakly for the high affinity IL-8 binding site at IL8RA. Thus, IL8RA and IL8RB are both highly selective for IL-8 and have similar sequences but differ dramatically in their selectivity for all other ELR+ CXC chemokines tested. These findings have important implications for developing novel neutrophil-specific anti-inflammatory drugs directed against the CXC chemokine signaling system.</p>
                    <p><a href="https://pubmed.ncbi.nlm.nih.gov/8702798/" target="_blank">[For more details, see PubMed]</a></p>
                </div>
                
                <div id="tab8702798" class="tabcontent ">
                    <h2>The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor.</h2>
                    <h3>The Journal of biological chemistry; 1996</h3>
                    <p>Interleukin-8 (IL-8), growth-related oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2 (NAP-2), epithelial cell-derived neutrophil activating peptide- 78 (ENA-78), and granulocyte chemoattractant protein-2 are potent neutrophil chemoattractants 40-90% identical in amino acid sequence that comprise a subgroup of human CXC chemokines defined by the conserved sequence motif glutamic acid-leucine-arginine (ELR). Two human chemotactic receptor subtypes for IL-8, named IL-8 receptors (IL8R) A and B, have been cloned. They are 78% identical in amino acid sequence, coexpressed in neutrophils, and distinguished by their different selectivities for GROalpha and NAP-2. Their selectivity for other ELR+ CXC chemokines has not been previously reported. By measuring calcium flux in human embryonic kidney 293 cells transfected with plasmids encoding IL8RA or IL8RB, we have now defined receptor selectivity for GRObeta, GROgamma, and ENA-78. The rank order of agonist potency, based on inspection of the mean effective concentration values (EC50), for IL8RB was GROgamma (1 nM) > IL-8 (4 nM) approximately GROalpha (5 nM) approximately GRObeta (4 nM) approximately NAP-2 (7 nM) > ENA-78 (11 nM), and for IL8RA was IL-8 (4 nM) >>> ENA-78 (40 nM) approximately NAP-2 (45 nM) > GROalpha (63 nM) approximately GROgamma (65 nM) >> GRObeta. The maximal response of IL8RA to IL-8 was at least 2-fold greater than the other five chemokines. All six agonists for IL8RB competed for high affinity 125I-IL-8, -GROalpha, -NAP-2, and -ENA-78 binding sites at IL8RB. GROalpha, GRObeta, GROgamma, NAP-2, and ENA-78 competed weakly for the high affinity IL-8 binding site at IL8RA. Thus, IL8RA and IL8RB are both highly selective for IL-8 and have similar sequences but differ dramatically in their selectivity for all other ELR+ CXC chemokines tested. These findings have important implications for developing novel neutrophil-specific anti-inflammatory drugs directed against the CXC chemokine signaling system.</p>
                    <p><a href="https://pubmed.ncbi.nlm.nih.gov/8702798/" target="_blank">[For more details, see PubMed]</a></p>
                </div>
                

    <footer>
        <span>© Copyright 2024, YCU Bioinformatics Laboratory</span>
        <span>Page built with <a href="https://quarto.org/">Quarto</a> by バイオインフォマティクス解析センター</span>
    </footer>
</body>
</html>
